To the Editor, We read the article by Rades et al. with great interest [1] . We agree that development of a prognostic score for brain metastases of non-small-cell lung cancer [BM-NSCLC] is essential. The cited authors appropriately incorporated features of systemic therapy into previous scoring systems when developing their system [WBRT-30-NSCLC], which is thus more precise than the earlier systems. This novel system will help clinicians who must engage in palliativecare decision-making.
However, we wish to emphasize the importance of the NSCLC molecular subtype in the present era of precision medicine; this has been incorporated into current treatment guidelines [2, 3] . Several prognostic scoring systems for BM-NSCLC that include the molecular subtypes have been developed and validated (example: the "Lung-molGPA") [4, 5] . When treating BM-NSCLC patients with "druggable" mutations (such as drug-sensitive mutations in the epidermal growth factor receptor gene), further studies may be needed to compare the Lung-molGPA and the WBRT-30-NSCLC.
